Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer

  1. Jiawen Bu
  2. Yixiao Zhang
  3. Nan Niu
  4. Kewei Bi
  5. Lisha Sun
  6. Xinbo Qiao
  7. Yimin Wang
  8. Yinan Zhang
  9. Xiaofan Jiang
  10. Dan Wang
  11. Qingtian Ma
  12. Huajun Li
  13. Caigang Liu  Is a corresponding author
  1. Shengjing Hospital of China Medical Universit, China
  2. Shengjing Hospital of China Medical University, China
  3. Jiangsu Hengrui Pharmaceuticals Co Ltd, China

Peer review process

This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.

History

  1. Version of Record published
  2. Accepted Manuscript published
  3. Accepted
  4. Preprint posted
  5. Received

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jiawen Bu
  2. Yixiao Zhang
  3. Nan Niu
  4. Kewei Bi
  5. Lisha Sun
  6. Xinbo Qiao
  7. Yimin Wang
  8. Yinan Zhang
  9. Xiaofan Jiang
  10. Dan Wang
  11. Qingtian Ma
  12. Huajun Li
  13. Caigang Liu
(2023)
Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer
eLife 12:e85246.
https://doi.org/10.7554/eLife.85246

Share this article

https://doi.org/10.7554/eLife.85246